Mesenchymal Stem Cell Therapy for Ischemic Heart Disease: Advances and Challenges

Author(s): Mikhail Konoplyannikov, Svetlana Kotova*, Vladimir Baklaushev, Anatoly Konoplyannikov, Vladimir Kalsin, Peter Timashev, Alexander Troitskiy.

Journal Name: Current Pharmaceutical Design

Volume 24 , Issue 26 , 2018

Become EABM
Become Reviewer

Abstract:

Ischemic Heart Disease (IHD) has been recognized as the main cause of mortality in the modern world. Application of cell therapy technologies for the IHD treatment has been actively studied from the beginning of 2000s. The review is dedicated to the use of mesenchymal stem cells (MSC) in the therapy of IHD. The strategies of the MSC modification in vitro for improvement of their regenerative potential are extensively discussed, including preconditioning to enhance the cell survival, boosting their paracrine effect and manipulating their cardiomyogenic differentiation. The optimization of the MSC delivery and opportunities related to the use of biomaterials as cell carriers are also discussed. The results of the most important clinical studies on the MSC-based IHD therapy are presented, including those completed and published in the literature and the ongoing clinical trials registered at clinicaltrials.gov by June 2018.

Keywords: Ischemic heart disease, mesenchymal stem cells, cell therapy, regenerative medicine, clinical trials, MSC-based IHD.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 24
ISSUE: 26
Year: 2018
Page: [3132 - 3142]
Pages: 11
DOI: 10.2174/1381612824666180913151059
Price: $58

Article Metrics

PDF: 13
HTML: 2
EPUB: 1
PRC: 1